Prospects and effects of combined treatment with cabozantinib and nivolumab

In recent years, innovative combination therapies have been continuously adopted in the field of cancer treatment to improve efficacy. The combined use of cabozantinib and nivolumab is becoming a hot topic in clinical trials and research. These two drugs fight tumors through different mechanisms, and their combination can provide patients with a more comprehensive treatment plan.

Cabozantinib is a small molecule tyrosine kinase inhibitor that mainly targets multiple signaling pathways related to angiogenesis and tumor cell proliferation. Cabozantinib has shown significant efficacy in the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. As an immune checkpoint inhibitor, nivolumab can relieve the suppression of the immune system by tumor cells by blocking the PD-1 receptor, allowing the immune system to effectively recognize and attack tumor cells. Combining these two drugs can achieve a synergistic effect between targeted therapy and immunotherapy.

Studies have shown that the combination treatment of cabozantinib and nivolumab is well tolerated and has significant efficacy in multiple cancer types. Especially in the treatment of renal cell carcinoma, combination therapy can not only slow down tumor progression but also improve patient survival rates. This treatment option is being evaluated in multiple clinical trials. Preliminary results show that patients' tumor shrinkage rate significantly increased and their quality of life improved after receiving combination therapy.

In addition, the combination treatment strategy also gives patients more options to deal with drug resistance. Treatment with a single drug may cause tumor cells to develop drug resistance, but combined use of drugs can interfere with the growth and survival of tumor cells in multiple ways, thereby reducing the risk of drug resistance. This joint application based on complementary mechanisms not only improves the therapeutic effect, but also provides patients with a more personalized treatment plan.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/35175500/